Tigecycline's Activity Against Gram-Positive Bacteria
Tigecycline, a glycylcycline antibiotic, inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. It covers most gram-positive pathogens, including multidrug-resistant strains, but shows reduced potency against some key ones compared to standard alternatives.[1]
How Tigecycline Stacks Up Against MRSA and VRE
Tigecycline has strong MIC90 values (minimum concentration inhibiting 90% of isolates) of 0.5-1 mg/L against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE), similar to linezolid (1-2 mg/L) and daptomycin (1 mg/L).[2] Against vancomycin-susceptible enterococci, tigecycline's MIC90 is 0.25 mg/L, outperforming vancomycin (4 mg/L) but trailing ampicillin (2 mg/L).[3] It fails against many Enterococcus faecalis isolates, where MIC90 exceeds 4 mg/L due to efflux pumps.
| Pathogen | Tigecycline MIC90 (mg/L) | Vancomycin | Daptomycin | Linezolid |
|----------|---------------------------|------------|------------|-----------|
| MRSA | 0.5-1 | 1-2 | 0.5 | 2 |
| VRE (faecium) | 0.25-0.5 | >256 | 4 | 2 |
| Pneumococcus | 0.06 | 0.5 | 0.25 | 1 |[2][4]
Comparison to Beta-Lactams and Glycopeptides
Beta-lactams like oxacillin work well against methicillin-susceptible S. aureus (MSSA, MIC90 0.25 mg/L) but fail completely against MRSA. Tigecycline covers both MSSA and MRSA evenly. Vancomycin remains first-line for serious gram-positive infections but loses ground to tigecycline in strains with elevated MICs (4-8 mg/L), where tigecycline maintains low MICs.[3] Against Streptococcus pneumoniae, tigecycline (MIC90 0.06 mg/L) beats vancomycin but matches penicillin-susceptible strains.
Why Tigecycline Underperforms on Some Gram-Positives
Tigecycline's bacteriostatic action limits it against high-burden infections like bacteremia or endocarditis, where bactericidal drugs like daptomycin (killing 99.9% in 24 hours) or vancomycin excel.[5] Efflux in E. faecalis raises MICs above clinical breakpoints (EUCAST: susceptible ≤1 mg/L), making it unreliable there.[1] No activity against Listeria or some Clostridium species.
Clinical Outcomes in Gram-Positive Infections
In trials like TEST (2004-2010), tigecycline matched comparators (vancomycin + piperacillin-tazobactam) for skin/soft tissue infections (cure rates 80-85%) but showed higher mortality in ventilator-associated pneumonia (19% vs. 12% for comparators), including gram-positive cases.[6] FDA warns against using it for hospital-acquired pneumonia due to inferiority. Success rates for complicated intra-abdominal infections with gram-positive involvement: 85-90%, on par with imipenem.[7]
When to Choose Tigecycline Over Others
Reserve tigecycline for polymicrobial or resistant gram-positive infections (e.g., MRSA+VRE) unresponsive to linezolid or daptomycin. Its broad spectrum (including anaerobes/gram-negatives) aids empiric therapy, but alternatives like ceftaroline (new cephalosporin, MRSA MIC90 1 mg/L) or dalbavancin (long-acting lipoglycopeptide) offer better gram-positive focus with less resistance risk.[4]
[1]: EUCAST breakpoints (eucast.org)
[2]: Jones et al., Diagn Microbiol Infect Dis (2010); doi:10.1016/j.diagmicrobio.2010.01.025
[3]: Clinical breakpoints, CLSI M100 (2023)
[4]: Sader et al., Antimicrob Agents Chemother (2018); doi:10.1128/AAC.02558-17
[5]: Peterson, Clin Infect Dis (2008); doi:10.1086/529208
[6]: FDA tigecycline label (fda.gov)
[7]: Postma et al., BMC Infect Dis (2013); doi:10.1186/1471-2334-13-113